Physician profile
Anna S Tseng
NPI 1053417964
$10,017.30
in general payments reported to CMS, 2019-2025
72 companies · $3,578 in 2025
The $3,578 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $662 · 2021: $496 · 2022: $1,281 · 2023: $1,231 · 2024: $1,719 · 2025: $3,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,926 · Consulting Fee: $1,525 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,926.20 |
| Consulting Fee | $1,525.00 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,077.20 | 2019-2025 | |
| Abbvie INC. | $1,494.83 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $569.46 | 2019-2025 | |
| Eisai INC. | $525.27 | 2020-2025 | |
| Ucb, INC. | $509.62 | 2019-2025 | Fintepla, Briviact |
| Lilly USA, LLC | $381.63 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Argenx US, INC. | $324.77 | 2024-2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $307.01 | 2019-2023 | Enspryng, Ocrevus |
| Alexion Pharmaceuticals, INC. | $213.50 | 2019-2025 | Soliris, Ultomiris |
| Biogen, INC. | $195.33 | 2019-2025 | Tysabri, Vumerity |
| Merz Pharmaceuticals, LLC | $190.68 | 2022-2025 | Xeomin |
| Acadia Pharmaceuticals INC | $174.69 | 2020-2025 | Nuplazid, Daybue |
| Tg Therapeutics, INC. | $173.75 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $151.53 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $117.09 | 2022 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.